Multiple myeloma registry study

This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.

This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.

This study creates a real-world registry (a group database) of people with active, symptomatic multiple myeloma. It helps researchers learn from patients and doctors over time and may support future research and treatment improvements.

This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.

This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.

This study checks on the long-term safety and how well the body handles the GC012F treatment over time. For people who already had this treatment before, it helps doctors see if the effects last and if there are any late side effects.